Effect of quercetin on platelet spreading on collagen and fibrinogen and on multiple platelet kinases

Fitoterapia

Volumn 81, Issue 2, 2010, Pages 75-80

  Navarro Núñez, Leyre ^a   Lozano, María L ^a   Martínez, Constantino ^a   Vicente, Vicente ^a   Rivera, José ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

Collagen; Fibrinogen; Kinase; Platelet; Quercetin; Spreading

Indexed keywords

ADENOSINE DIPHOSPHATE; COLLAGEN; FIBRINOGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE C; QUERCETIN; THROMBOXANE A2;

ARTICLE; CELL SPREADING; CONTROLLED STUDY; DRUG INHIBITION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; THROMBOCYTE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOSINE DIPHOSPHATE; BLOOD PLATELETS; COLLAGEN; FIBRINOGEN; HUMANS; INTEGRINS; PLATELET ADHESIVENESS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; QUERCETIN; SIGNAL TRANSDUCTION; THROMBOXANE A2;

EID: 72249120209     PISSN: 0367326X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fitote.2009.08.006     Document Type: Article

References (41)

1. Atkinson B.T., Jarvis G.E., and Watson S.P. Activation of GPVI by collagen is regulated by alpha2beta1 and secondary mediators. J Thromb Haemost 1 (2003) 1278-1287
2. Ruggeri Z.M., and Mendolicchio G.L. Adhesion mechanisms in platelet function. Circ Res 100 (2007) 1673-1685
3. Watson S.P., Auger J.M., McCarty O.J., and Pearce A.C. GPVI and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost 3 (2005) 1752-1762
4. Coller B.S., and Shattil S.J. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 112 (2008) 3011-3025
5. Bennett J.S. Structure and function of the platelet integrin alphaIIbbeta3. J Clin Invest 115 (2005) 3363-3369
6. Obergfell A., Eto K., Mocsai A., Buensuceso C., Moores S.L., Brugge J.S., et al. Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton. J Cell Biol 157 (2002) 265-275
7. Reddy K.B., Smith D.M., and Plow E.F. Analysis of Fyn function in hemostasis and alphaIIbbeta3-integrin signaling. J Cell Sci 121 (2008) 1641-1648
8. Wang W.Y., Wu Y.C., and Wu C.C. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor. Mol Pharmacol 70 (2006) 1380-1389
9. Wang W.Y., Hsieh P.W., Wu Y.C., and Wu C.C. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol 74 (2007) 601-611
10. Dutta-Roy A.K. Dietary components and human platelet activity. Platelets 13 (2002) 67-75
11. Kris-Etherton P.M., Lefevre M., Beecher G.R., Gross M.D., Keen C.L., and Etherton T.D. Bioactive compounds in nutrition and health-research methodologies for establishing biological function: the antioxidant and anti-inflammatory effects of flavonoids on atherosclerosis. Annu Rev Nutr 24 (2004) 511-538
12. Hertog M.G., Feskens E.J., Hollman P.C., Katan M.B., and Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342 (1993) 1007-1011
13. Hertog M.G., Hollman P.C., Katan M.B., and Kromhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr Cancer 20 (1993) 21-29
14. Agullo G., Gamet-Payrastre L., Manenti S., Viala C., Remesy C., Chap H., et al. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol 53 (1997) 1649-1657
15. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351 (2000) 95-105
16. Hagiwara M., Inoue S., Tanaka T., Nunoki K., Ito M., and Hidaka H. Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases. Biochem Pharmacol 37 (1988) 2987-2992
17. Ferry D.R., Smith A., Malkhandi J., Fyfe D.W., deTakats P.G., Anderson D., et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2 (1996) 659-668
18. Hubbard G.P., Stevens J.M., Cicmil M., Sage T., Jordan P.A., Williams C.M., et al. Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway. J Thromb Haemost 1 (2003) 1079-1088
19. Rodems S.M., Hamman B.D., Lin C., Zhao J., Shah S., Heidary D., et al. A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases. Assay Drug Dev Technol 1 (2002) 9-19
20. Guerrero J.A., Lozano M.L., Castillo J., Benavente-Garcia O., Vicente V., and Rivera J. Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J Thromb Haemost 3 (2005) 369-376
21. Guerrero J.A., Navarro-Núñez L., Lozano M.L., Martinez C., Vicente V., Gibbins J.M., et al. Flavonoids inhibit the platelet TxA(2) signalling pathway and antagonize TxA(2) receptors (TP) in platelets and smooth muscle cells. Br J Clin Pharmacol 64 (2007) 133-144
22. McCarty O.J., Larson M.K., Auger J.M., Kalia N., Atkinson B.T., Pearce A.C., et al. Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow. J Biol Chem 280 (2005) 39,474-39,484
23. Abramoff M., Magelhaes P., and Ram S. Image processing with ImageJ. Biophoton Int 11 (2004) 36-42
24. Walker E.H., Pacold M.E., Perisic O., Stephens L., Hawkins P.T., Wymann M.P., et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6 (2000) 909-919
25. Bain J., McLauchlan H., Elliott M., and Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 371 (2003) 199-204
26. Bach S., Knockaert M., Reinhardt J., Lozach O., Schmitt S., Baratte B., et al. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 280 (2005) 31,208-31,219
27. DePinto W., Chu X.J., Yin X., Smith M., Packman K., Goelzer P., et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther 5 (2006) 2644-2658
28. Gharbi S.I., Zvelebil M.J., Shuttleworth S.J., Hancox T., Saghir N., Timms J.F., et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 404 (2007) 15-21
29. Kothe M., Kohls D., Low S., Coli R., Rennie G.R., Feru F., et al. Selectivity-determining residues in Plk1. Chem Biol Drug Des 70 (2007) 540-546
30. Gamet-Payrastre L., Manenti S., Gratacap M.P., Tulliez J., Chap H., and Payrastre B. Flavonoids and the inhibition of PKC and PI 3-kinase. Gen Pharmacol 32 (1999) 279-286
31. Jackson S.F., and Schoenwaelder S.M. Type I phosphoinositide 3-kinases: potential antithrombotic targets?. Cell Mol Life Sci 63 (2006) 1085-1090
32. Voss B., McLaughlin J.N., Holinstat M., Zent R., and Hamm H.E. PAR1, but not PAR4, activates human platelets through a Gi/o/phosphoinositide-3 kinase signaling axis. Mol Pharmacol 71 (2007) 1399-1406
33. Yin H., Stojanovic A., Hay N., and Du X. The role of Akt in the signaling pathway of the glycoprotein Ib-IX induced platelet activation. Blood 111 (2008) 658-665
34. Fan P.S., Gu Z.L., and Liang Z.Q. Effect of quercetin on adhesion of platelets to microvascular endothelial cells in vitro. Acta Pharmacol Sin 22 (2001) 857-860
35. Liang Z.Q., Zhu Y., Gu Z.L., Lu Q., and Fan P.S. Effects of quercetin on platelet-endothelial cell adhesion and their expression of adhesion molecules. Yao Xue Xue Bao 38 (2003) 574-577
36. Pignatelli P., Pulcinelli F.M., Celestini A., Lenti L., Ghiselli A., Gazzaniga P.P., et al. The flavonoids quercetin and catechin synergistically inhibit platelet function by antagonizing the intracellular production of hydrogen peroxide. Am J Clin Nutr 72 (2000) 1150-1155
37. Inoue O., Suzuki-Inoue K., Dean W.L., Frampton J., and Watson S.P. Integrin alpha2beta1 mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCgamma2. J Cell Biol 160 (2003) 769-780
38. Hubbard G.P., Wolffram S., de V.R., Bovy A., Gibbins J.M., and Lovegrove J.A. Ingestion of onion soup high in quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in man: a pilot study. Br J Nutr 96 (2006) 482-488
39. Moon Y.J., Wang L., DiCenzo R., and Morris M.E. Quercetin pharmacokinetics in humans. Biopharm Drug Dispos 29 (2008) 205-217
40. Erlund I., Kosonen T., Alfthan G., Mäenpää J., Perttunen K., Kenraali J., et al. Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. Eur J Clin Pharmacol 56 (2000) 545-553
41. Hertog M.G., Kromhout D., Aravanis C., Blackburn H., Buzina R., Fidanza F., et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med 155 (1995) 381-386